Literature DB >> 2245175

Cell kinetics: an independent prognostic variable in stage II melanoma of the skin.

A Costa1, R Silvestrini, G Mezzanotte, M Vaglini, E Grignolio, C Clemente, N Cascinelli.   

Abstract

The prognostic role of cell kinetics (expressed as 3H-thymidine labelling index, 3H-TdR LI) was assessed on 145 patients with pathologic stage II melanoma subjected only to therapeutic lymph node dissection. The 3H-TdR LI determined on metastatic nodes was related to relapse-free survival and to survival. In particular, 3-year relapse-free survival was significantly different from patients with slowly and rapidly proliferating melanomas (40% vs 22%, P = 0.007), and this finding was consistently found for overall survival (68% vs 46%, P = 0.007). Moreover, in patients with high 3H-TdR LI tumours, the risk of relapse and death within the first year from lymphadenectomy was two-fold that of patients with low 3H-TdR LI tumours. Multiple regression analysis showed that 3H-TdR LI retained its prognostic significance on relapse-free and on overall survival even when the number of involved nodes and type of nodal metastases were considered. Present findings suggest that 3H-TdR LI can contribute to select high-risk stage II melanoma patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2245175      PMCID: PMC1971537          DOI: 10.1038/bjc.1990.386

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Prognostic indicators in centroblastic-centrocytic lymphoma.

Authors:  N R Griffin; M R Howard; P Quirke; C J O'Brien; J A Child; C C Bird
Journal:  J Clin Pathol       Date:  1988-08       Impact factor: 3.411

2.  Prognostic implications of proliferative activity and DNA aneuploidy in colonic adenocarcinomas.

Authors:  K D Bauer; S T Lincoln; J M Vera-Roman; C B Wallemark; J S Chmiel; M L Madurski; T Murad; D G Scarpelli
Journal:  Lab Invest       Date:  1987-09       Impact factor: 5.662

3.  The histogenesis and biologic behavior of primary human malignant melanomas of the skin.

Authors:  W H Clark; L From; E A Bernardino; M C Mihm
Journal:  Cancer Res       Date:  1969-03       Impact factor: 12.701

4.  Evaluation of survival data and two new rank order statistics arising in its consideration.

Authors:  N Mantel
Journal:  Cancer Chemother Rep       Date:  1966-03

5.  Prognostic implications of cell kinetics, histopathology and pathologic stage in non-Hodgkin's lymphomas.

Authors:  R Silvestrini; A Costa; R Giardini; P Boracchi; G Del Bino; E Marubini; F Rilke
Journal:  Hematol Oncol       Date:  1989 Nov-Dec       Impact factor: 5.271

6.  Cell proliferation in human melanoma.

Authors:  S Shirakawa; J K Luce; I Tannock; E Frei
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

7.  Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer.

Authors:  O P Kallioniemi; T Hietanen; J Mattila; M Lehtinen; K Lauslahti; T Koivula
Journal:  Eur J Cancer Clin Oncol       Date:  1987-03

8.  The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma.

Authors:  P A Hall; M A Richards; W M Gregory; A J d'Ardenne; T A Lister; A G Stansfeld
Journal:  J Pathol       Date:  1988-03       Impact factor: 7.996

9.  Prognostic factors related to survival and groin recurrence following therapeutic lymph node dissection for lower limb malignant melanoma.

Authors:  M W Kissin; D A Simpson; D Easton; H White; G Westbury
Journal:  Br J Surg       Date:  1987-11       Impact factor: 6.939

10.  Ki67 immunostaining in primary breast cancer: pathological and clinical associations.

Authors:  N Bouzubar; K J Walker; K Griffiths; I O Ellis; C W Elston; J F Robertson; R W Blamey; R I Nicholson
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

View more
  1 in total

1.  Contribution of 3H-thymidine labelling index and flow cytometric S-phase in predicting survival of patients with non-Hodgkin's lymphoma.

Authors:  A Costa; R Silvestrini; R Giardini; G Messina-Gabrielli; P Boracchi; S Veneroni
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.